[
  {
    "section": "section:1",
    "title": "Abstract"
  },
  {
    "section": "section:1",
    "title": "Introduction"
  },
  {
    "section": "section:1",
    "title": "Results"
  },
  {
    "section": "section:2",
    "title": "Predicting optimal dose from a PIK3CA mutant breast model"
  },
  {
    "section": "section:2",
    "title": "Phase Ia Clinical Trial Design"
  },
  {
    "section": "section:2",
    "title": "Baseline Patient Demographics and Disease Characteristics"
  },
  {
    "section": "section:2",
    "title": "Safety"
  },
  {
    "section": "section:2",
    "title": "Pharmacokinetics"
  },
  {
    "section": "section:2",
    "title": "Pharmacodynamic modulation of the PI3K pathway"
  },
  {
    "section": "section:2",
    "title": "Biomarker Profiling of Patient Tumors"
  },
  {
    "section": "section:2",
    "title": "Tumor Responses observed with taselisib treatment"
  },
  {
    "section": "section:2",
    "title": "Examples of Tumor Responses in PIK3CA-Mutant Breast Cancer Patients"
  },
  {
    "section": "section:1",
    "title": "Discussion"
  },
  {
    "section": "section:1",
    "title": "Methods"
  },
  {
    "section": "section:2",
    "title": "In-Vivo Efficacy"
  },
  {
    "section": "section:2",
    "title": "Pharmacodynamic Marker Analysis in KPL-4 Tumor Xenografts"
  },
  {
    "section": "section:2",
    "title": "Study Population"
  },
  {
    "section": "section:2",
    "title": "Study Design"
  },
  {
    "section": "section:2",
    "title": "Study Treatment"
  },
  {
    "section": "section:2",
    "title": "Safety"
  },
  {
    "section": "section:2",
    "title": "Pharmacokinetics"
  },
  {
    "section": "section:2",
    "title": "FDG-PET Imaging"
  },
  {
    "section": "section:2",
    "title": "Reverse Phase Protein Array Analysis of Tumor Biopsies"
  },
  {
    "section": "section:2",
    "title": "Tumor Assessments"
  },
  {
    "section": "section:2",
    "title": "Determination of PIK3CA Mutation Status"
  },
  {
    "section": "section:3",
    "title": "Assessment of somatic mutations from tissue"
  },
  {
    "section": "section:3",
    "title": "Assessment of somatic mutations from plasma"
  },
  {
    "section": "section:3",
    "title": "Determination of PTEN status"
  },
  {
    "section": "section:2",
    "title": "Statistical Methods"
  },
  {
    "section": "section:1",
    "title": "References"
  },
  {
    "section": "section:1",
    "title": "Figure 1"
  },
  {
    "section": "section:1",
    "title": "Figure 2"
  },
  {
    "section": "section:1",
    "title": "Figure 3"
  },
  {
    "section": "section:1",
    "title": "Figure 4"
  },
  {
    "section": "section:1",
    "title": "Figure 5"
  },
  {
    "section": "section:1",
    "title": "Table 1"
  },
  {
    "section": "section:1",
    "title": "Table 2"
  }
]